0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NewCardio
Its shares trade under the ticker NWCI. It has been listed since 3 November 2006. In the fiscal year to 31 December 2010, it reported revenue of $257,399 and a net loss of $11.5m. At that date it held total assets of $2.9m and shareholders' equity of −$3.2m.
NewCardio, Inc. is a cardiac diagnostic technology provider, which focuses on the research, development and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular diseases, as well as the cardiac safety assessment of drugs under development. The company is headquartered in Santa Clara, California. The company went IPO on 2006-11-03. The firm is focused on the development of a platform technology for its products, which will improve the diagnostic accuracy and value of the standard 12-lead electrocardiogram (ECG). The Company’s core technology platform provides real-time, three-dimensional (3D) analysis of the heart's electrical activity, as detected at the body surface by standard 12-lead ECG electrodes. ECG input signals are typically sampled at 500 hertz (500 times per second).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 3 Nov 2006
- Employees
- 10
Leadership
Pay as last reported
- Vincent RenzPresident, since 2008$719,500
- Dr. Jess JonesChief Executive Officer, Director, since 2008
- Gregory SadowskiChief Operating Officer
- Mr. Richard BrounsteinExecutive Vice President, Secretary$204,000
- Mr. Michael HansonIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NewCardio Inc has several strengths that contribute to its success in the market. Firstly, the company offers innovative cardiovascular diagnostic solutions, incorporating state-of-the-art technology and advanced algorithms. By providing accurate and reliable results, NewCardio can fulfill the needs of healthcare professionals and patients alike.
- Additionally, NewCardio has a strong team of experienced professionals who possess deep knowledge and expertise in the field of cardiac monitoring. This allows the company to develop cutting-edge products and offer exceptional support to its clients.
Weaknesses
- Despite its strengths, NewCardio Inc also faces certain weaknesses that can impact its performance. One significant weakness is the company's limited market presence and brand recognition. This makes it challenging for NewCardio to effectively compete with larger, more established players in the industry.
- Additionally, NewCardio's dependence on external suppliers for certain components of its products exposes it to supply chain risks. Any disruptions or delays in the supply chain can adversely affect the company's ability to deliver its solutions in a timely manner, potentially leading to dissatisfied customers.
Opportunities
- NewCardio Inc can leverage several opportunities to drive its growth and expand its market share. The increasing prevalence of cardiovascular diseases globally presents a significant opportunity for the company. By offering advanced diagnostic solutions, NewCardio can tap into a growing market and cater to the rising demand for effective cardiac monitoring tools.
- Furthermore, the ongoing advancements in technology create opportunities for NewCardio to enhance its existing products or develop new ones. By staying at the forefront of innovation, the company can differentiate itself from competitors and gain a competitive edge in the market.
Threats
- NewCardio Inc must be aware of various threats that could impact its business operations. One significant threat is the presence of well-established competitors in the market, who may have greater resources and brand recognition. This puts NewCardio at a disadvantage when it comes to capturing market share and securing partnerships or contracts.
- Additionally, regulatory and compliance requirements in the healthcare industry pose threats to NewCardio. Adhering to these regulations can be costly and time-consuming, potentially creating barriers for the company to enter certain markets or expand its product offerings.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.